1. Pink Sheet
  2. >>Market Access

New Medicare Negotiation Program ‘Iterations’ Inevitable, Former CMS Official Blum Says

 
• By Cathy Kelly

Jonathan Blum, who was principal deputy administrator during the Biden Administration, explained the agency’s approach to setting up the price negotiation program and said changes likely will be implemented by the Trump Administration.

Blum said the next phase of the price negotiation program will include revisions. (Shutterstock)
Key Takeaways
  • The Medicare price negotiation program will change in the future as policies like considering all versions of the same active moiety one product are reconsidered, former CMS principal deputy administrator Jonathan Blum predicted.
  • CMS implemented the program under very tight timelines, which made conducting lengthy analyses on some policies unworkable, Blum said.
  • The negotiation framework that the agency built will be "durable," but other elements of the program "feel more shaky" and will need more fleshing out, he said.

Medicare price negotiation policies will evolve in the coming years, former US Centers for Medicare and Medicaid Services principal deputy adminitrator and chief operating officer Jonathan Blum predicts.

The current approach that considers all versions of an active ingredient as a single product in the negotiation process is a policy that could change,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

More from Geography

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.